

# Eli Avisar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7550051/publications.pdf>

Version: 2024-02-01

43  
papers

935  
citations

840776

11  
h-index

454955

30  
g-index

43  
all docs

43  
docs citations

43  
times ranked

1350  
citing authors

#	ARTICLE	IF	CITATIONS
1	A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma. Breast Cancer Research and Treatment, 2008, 111, 541-547.	2.5	222
2	Clinicopathologic Predictors of Sentinel Lymph Node Metastasis in Thin Melanoma. Journal of Clinical Oncology, 2013, 31, 4387-4393.	1.6	204
3	Impact of Sentinel Node Status and Other Risk Factors on the Clinical Outcome of Head and Neck Melanoma Patients. JAMA Otolaryngology, 2006, 132, 370.	1.2	93
4	Factors Predictive of the Status of Sentinel Lymph Nodes in Melanoma Patients from a Large Multicenter Database. Annals of Surgical Oncology, 2011, 18, 3593-3600.	1.5	78
5	Brief cognitive-behavioral and relaxation training interventions for breast cancer: A randomized controlled trial. Journal of Consulting and Clinical Psychology, 2015, 83, 677-688.	2.0	78
6	Pure mucinous carcinoma of the breast: A clinicopathologic correlation study. Annals of Surgical Oncology, 1998, 5, 447-451.	1.5	52
7	Evaluation of Simplified Lymphatic Microsurgical Preventing Healing Approach (S-LYMPHA) for the Prevention of Breast Cancer-Related Clinical Lymphedema After Axillary Lymph Node Dissection. Annals of Surgery, 2019, 270, 1156-1160.	4.2	35
8	Stratifying SLN incidence in intermediate thickness melanoma patients. American Journal of Surgery, 2018, 215, 699-706.	1.8	26
9	Prognostic Factors in Node-Negative Male Breast Cancer. Clinical Breast Cancer, 2006, 7, 331-335.	2.4	23
10	Internal mammary sentinel node biopsy for breast cancer. American Journal of Surgery, 2008, 196, 490-494.	1.8	16
11	Disparities in Overall Survival for Male Breast Cancer Patients in the State of Florida (1996-2007). Clinical Breast Cancer, 2015, 15, e177-e187.	2.4	13
12	The role of matricellular proteins and tissue stiffness in breast cancer: a systematic review. Future Oncology, 2018, 14, 1601-1627.	2.4	12
13	Surgical Management of the Axilla in Patients with Occult Breast Cancer (cT0 N+) After Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 2020, 27, 1830-1841.	1.5	12
14	Overcoming disparities: Multidisciplinary breast cancer care at a public safety net hospital. Breast Cancer Research and Treatment, 2021, 187, 197-206.	2.5	11
15	Breast Cancer Management During the COVID-19 Pandemic: The Senologic International Society Survey. The Journal of Breast Health, 2021, 17, 188-196.	1.0	9
16	Evaluation of Simplified Lymphatic Microsurgical Preventing Healing Approach (SLYMPHA) for the prevention of breast cancer-related lymphedema after axillary lymph node dissection using bioimpedance spectroscopy. European Journal of Surgical Oncology, 2022, 48, 1713-1717.	1.0	6
17	Predictive value of BI-RADS classification for breast imaging in women under age 50. Breast Cancer Research and Treatment, 2011, 130, 819-823.	2.5	5
18	A tailored approach to regional nodal irradiation. Breast Cancer Research and Treatment, 2016, 155, 1-2.	2.5	5

#	ARTICLE	IF	CITATIONS
19	Diagnostic application of cyclin D1 fluorescent in situ hybridization for histologically undetermined early lesions of acral melanoma in situ: A case series. <i>Annals of Diagnostic Pathology</i> , 2021, 50, 151681.	1.3	5
20	Is pelvic sentinel node biopsy necessary for lower extremity and trunk melanomas?. <i>American Journal of Surgery</i> , 2017, 213, 921-925.	1.8	4
21	Management of the positive axilla in 2017. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 413-415.	2.5	3
22	Axillary response rates to neoadjuvant chemotherapy in breast cancer patients with advanced nodal disease. <i>Journal of Surgical Oncology</i> , 2021, 124, 25-32.	1.7	3
23	The Senologic International Society Survey on Ductal Carcinoma & In Situ: Present and Future. <i>The Journal of Breast Health</i> , 2022, 18, 205-221.	1.0	3
24	Management of the Positive Axilla in 2017. <i>Cureus</i> , 2017, 9, e1216.	0.5	2
25	Post Mastectomy Radiation for Stage II Breast Cancer Patients with T1/T2 Lesions. <i>The Journal of Breast Health</i> , 2019, 15, 71-75.	1.0	2
26	Interleukin-21 Induces Cell Cycle Arrest and Apoptosis of Diffuse Large B-Cell Lymphomas (DLBCL) Via Activation of STAT3 and Upregulation of C-Myc. <i>Blood</i> , 2008, 112, 601-601.	1.4	2
27	Prognosis of metastatic internal mammary sentinel nodes (IMSN) in breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 103-103.	1.6	2
28	Axillary Response to Neoadjuvant Therapy in Node-Positive, Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Patients: Predictors and Oncologic Outcomes. <i>Annals of Surgical Oncology</i> , 2022, 29, 4092-4101.	1.5	2
29	Persistent and interdependent: Racial disparities and their mechanisms in postmastectomy breast reconstruction. <i>Surgery</i> , 2022, 172, 25-30.	1.9	2
30	Use of PET probe in surgical oncology. <i>Journal of Surgical Oncology</i> , 2008, 97, 369-371.	1.7	1
31	Predictors of Surgery Types after Neoadjuvant Therapy for Advanced Stage Breast Cancer: Analysis from Florida Population-Based Cancer Registry (1996-2009). <i>Breast Cancer: Basic and Clinical Research</i> , 2015, 9, BCBCR.S31503.	1.1	1
32	A rare complication resulting in a rare disease: radiation-induced male breast cancer. <i>BMJ Case Reports</i> , 2016, 2016, bcr2015211874.	0.5	1
33	Internal Mammary Node Irradiation: Does One Treatment Fit All?. <i>Journal of Clinical Oncology</i> , 2016, 34, 2671-2671.	1.6	1
34	Axillary Reverse Lymphatic Mapping in the Treatment for Axillary Accessory Breast Cancer: A Case Report and Review of Management. <i>The Journal of Breast Health</i> , 2021, 18, 0-0.	1.0	1
35	Response to Comment on "Annals of Surgery Response to Letter to the Editor". <i>Annals of Surgery</i> , 2019, 270, e30-e31.	4.2	0
36	The Usefulness of the Pretreatment Neutrophil/Lymphocyte Ratio as a Predictor of the 5-Year Survival in Stage 1-3 Triple Negative Breast Cancer Patients. <i>Breast Care</i> , 2021, 16, 43-49.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Long-term results of simplified lymphatic microsurgical preventing healing approach (SLYMPHA) for the prevention of breast cancer-related clinical lymphedema after axillary lymph node dissection.. Journal of Clinical Oncology, 2021, 39, 514-514.	1.6	0
38	Simplified lymphatic microsurgical preventing healing approach (SLYMPHA) for the prevention of breast cancer-related lymphedema after axillary lymph node dissection.. Journal of Clinical Oncology, 2021, 39, e12581-e12581.	1.6	0
39	Factors associated with increasing rates of contralateral prophylactic mastectomy.. Journal of Clinical Oncology, 2014, 32, 57-57.	1.6	0
40	Neoadjuvant and adjuvant, floxuridine, leucovorin, oxaliplatin, and docetaxel (FLOD) in patients with locally advanced operable gastroesophageal adenocarcinoma: A phase II study with pathologic responses and long term follow-up.. Journal of Clinical Oncology, 2016, 34, 124-124.	1.6	0
41	Evaluation of simplified lymphatic microsurgical preventing healing approach (SLYMPHA) for the prevention of breast cancer-related clinical lymphedema after axillary lymph node dissection.. Journal of Clinical Oncology, 2017, 35, 563-563.	1.6	0
42	The Impact of Advanced Image-Guided Breast Surgery and Oncoplastic Techniques on Margin Positivity in Breast Conserving Surgery. Cureus, 2020, 12, e11831.	0.5	0
43	ASO Visual Abstract: Axillary Response to Neoadjuvant Therapy in Node-Positive ER+/HER2- Breast Cancer Patients—Predictors and Oncologic Outcomes. Annals of Surgical Oncology, 2022, , 1.	1.5	0